{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:45:31Z","timestamp":1793339131399,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470826"],"award-info":[{"award-number":["82470826"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40265-025-02274-x","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T01:28:38Z","timestamp":1768786118000},"page":"217-230","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effect of Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) Inhibitors on Lipoprotein(a) Levels: An Umbrella Review of Meta-analyses of Randomized Controlled Trials"],"prefix":"10.1007","volume":"86","author":[{"given":"Wenmei","family":"Qiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8782-3314","authenticated-orcid":false,"given":"Yongze","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"issue":"2","key":"2274_CR1","doi-asserted-by":"crossref","DOI":"10.1016\/S0735-1097(96)82521-6","volume":"4","author":"FB Rivera","year":"2025","unstructured":"Rivera FB, Cha SW, Linnaeus Louisse C, Carado GP, Magalong JV, Tang VA, et al. Impact of proprotein convertase subtilisin\/kexin type 9 inhibitors on lipoprotein(a). JACC: Advances. 2025;4(2):101549.","journal-title":"JACC: Advances"},{"issue":"1","key":"2274_CR2","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40256-018-0303-2","volume":"19","author":"YX Cao","year":"2019","unstructured":"Cao YX, Liu HH, Li S, Li JJ. A meta-analysis of the effect of PCSK9-monoclonal antibodies on circulating lipoprotein (a) levels. Am J Cardiovasc Drugs. 2019;19(1):87\u201397.","journal-title":"Am J Cardiovasc Drugs"},{"key":"2274_CR3","doi-asserted-by":"publisher","DOI":"10.1161\/ATV.0000000000000147","author":"G Reyes-Soffer","year":"2022","unstructured":"Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement From the American Heart Association. ATVB [Internet]. 2022. https:\/\/doi.org\/10.1161\/ATV.0000000000000147.","journal-title":"ATVB [Internet]"},{"issue":"6","key":"2274_CR4","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/jamacardio.2019.1041","volume":"4","author":"C Lamina","year":"2019","unstructured":"Lamina C, Kronenberg F, for the Lp(a)-GWAS-Consortium. Estimation of the required Lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes: a Mendelian randomization analysis. JAMA Cardiol. 2019;4(6):575.","journal-title":"JAMA Cardiol."},{"issue":"5","key":"2274_CR5","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jacl.2019.06.011","volume":"13","author":"C Pavanello","year":"2019","unstructured":"Pavanello C, Pirazzi C, Bjorkman K, Sandstedt J, Tarlarini C, Mosca L, et al. Individuals with familial hypercholesterolemia and cardiovascular events have higher circulating Lp(a) levels. J Clin Lipidol. 2019;13(5):778-787.e6.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"2274_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41569-018-0052-6","volume":"16","author":"AJ Berberich","year":"2019","unstructured":"Berberich AJ, Hegele RA. The complex molecular genetics of familial hypercholesterolaemia. Nat Rev Cardiol. 2019;16(1):9\u201320.","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"2274_CR7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.5603\/EP.a2023.0036","volume":"74","author":"H Dai","year":"2023","unstructured":"Dai H, Zhu Y, Chen Z, Yan R, Liu J, He Z, et al. Impact of alirocumab\/evolocumab on lipoprotein (a) concentrations in patients with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized controlled trials. Endokrynol Pol. 2023;74(3):234\u201342.","journal-title":"Endokrynol Pol"},{"issue":"23","key":"2274_CR8","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"BG Nordestgaard","year":"2010","unstructured":"Nordestgaard BG, Chapman MJ, Ray K, Bor\u00e9n J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844\u201353.","journal-title":"Eur Heart J"},{"issue":"15","key":"2274_CR9","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1136\/heartjnl-2019-314763","volume":"105","author":"H Du","year":"2019","unstructured":"Du H, Li X, Su N, Li L, Hao X, Gao H, et al. Proprotein convertase subtilisin\/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis. Heart. 2019;105(15):1149\u201359.","journal-title":"Heart"},{"issue":"2","key":"2274_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2025-003490","volume":"12","author":"VQT Ho","year":"2025","unstructured":"Ho VQT, Tran NB, Nguyen N, Arrighini GS, Downes D, Dandamudi M, et al. PCSK9 targeting therapies for familial hypercholesterolaemia: a meta-analysis of efficacy on lipid biomarkers and safety in adults and children across 23 RCTs. Open Heart. 2025;12(2):e003490.","journal-title":"Open Heart"},{"issue":"4","key":"2274_CR11","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1007\/s12325-020-01259-4","volume":"37","author":"G Mu","year":"2020","unstructured":"Mu G, Xiang Q, Zhou S, Liu Z, Qi L, Jiang J, et al. Efficacy and safety of PCSK9 monoclonal antibodies in patients at high cardiovascular risk: an updated systematic review and meta-analysis of 32 randomized controlled trials. Adv Ther. 2020;37(4):1496\u2013521.","journal-title":"Adv Ther"},{"issue":"377","key":"2274_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069116","volume":"4","author":"SU Khan","year":"2022","unstructured":"Khan SU, Yedlapati SH, Lone AN, Hao Q, Guyatt G, Delvaux N, et al. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis. BMJ. 2022;4(377):e069116.","journal-title":"BMJ"},{"issue":"3","key":"2274_CR13","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/FJC.0000000000000963","volume":"77","author":"I Farmakis","year":"2021","unstructured":"Farmakis I, Doundoulakis I, Pagiantza A, Zafeiropoulos S, Antza C, Karvounis H, et al. Lipoprotein(a) reduction with proprotein convertase subtilisin\/kexin type 9 inhibitors: a systematic review and meta-analysis. J Cardiovasc Pharmacol. 2021;77(3):397\u2013407.","journal-title":"J Cardiovasc Pharmacol"},{"key":"2274_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;29:n71.","journal-title":"BMJ"},{"key":"2274_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jclinepi.2018.01.003","volume":"100","author":"S Sideri","year":"2018","unstructured":"Sideri S, Papageorgiou SN, Eliades T. Registration in the international prospective register of systematic reviews (PROSPERO) of systematic review protocols was associated with increased review quality. J Clin Epidemiol. 2018;100:103\u201310.","journal-title":"J Clin Epidemiol"},{"key":"2274_CR16","doi-asserted-by":"crossref","unstructured":"Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;j4008.","DOI":"10.1136\/bmj.j4008"},{"issue":"4","key":"2274_CR17","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jclinepi.2013.11.007","volume":"67","author":"D Pieper","year":"2014","unstructured":"Pieper D, Antoine SL, Mathes T, Neugebauer EAM, Eikermann M. Systematic review finds overlapping reviews were not mentioned in every other overview. J Clin Epidemiol. 2014Apr;67(4):368\u201375.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"2274_CR18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/jrsm.1390","volume":"11","author":"EA Hennessy","year":"2020","unstructured":"Hennessy EA, Johnson BT. Examining overlap of included studies in meta\u2010reviews: guidance for using the corrected covered area index. Res Synth Methods. 2020;11(1):134\u201345.","journal-title":"Res Synth Methods"},{"issue":"5","key":"2274_CR19","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1111\/jep.13016","volume":"24","author":"M Mercuri","year":"2018","unstructured":"Mercuri M, Gafni A. The evolution of GRADE (part 3): a framework built on science or faith? Eval Clin Pract. 2018;24(5):1223\u201331.","journal-title":"Eval Clin Pract"},{"issue":"1","key":"2274_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40256-023-00621-5","volume":"24","author":"A Atia","year":"2024","unstructured":"Atia A, Aboeldahab H, Wageeh A, Elneny M, Elmallahy M, Elawfi B, et al. Safety and efficacy of proprotein convertase subtilisin-kexin type 9 inhibitors after acute coronary syndrome: a meta-analysis of randomized controlled trials. Am J Cardiovasc Drugs. 2024;24(1):83\u2013102.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"7","key":"2274_CR21","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1080\/14712598.2025.2511063","volume":"25","author":"M Jha","year":"2025","unstructured":"Jha M, Agrawal SP, Maheta D, Bhattacharjee P, Jain H, Zacks J, et al. Efficacy and safety of evolocumab in statin-treated patients with cardiovascular risk factors: a systematic review and meta-analysis. Expert Opin Biol Ther. 2025;25(7):749\u201359.","journal-title":"Expert Opin Biol Ther"},{"key":"2274_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.amjcard.2025.04.013","volume":"250","author":"I Khalil","year":"2025","unstructured":"Khalil I, Rahman MT, Hossain I. The impact of inclisiran on lipid profiles in adults with hyperlipidemia: a meta-analysis and meta-regression of randomized controlled trials. Am J Cardiol. 2025;250:20\u20139.","journal-title":"Am J Cardiol"},{"issue":"24","key":"2274_CR23","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","volume":"41","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41(24):2275\u201384.","journal-title":"Eur Heart J"},{"key":"2274_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2025.120420","volume":"408","author":"S Xie","year":"2025","unstructured":"Xie S, Galimberti F, Olmastroni E, Carugo S, Catapano AL, Casula M. Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials. Atherosclerosis. 2025;408:120420.","journal-title":"Atherosclerosis"},{"issue":"9","key":"2274_CR25","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.numecd.2023.05.033","volume":"33","author":"T Chen","year":"2023","unstructured":"Chen T, Wang Z, Xie J, Xiao S, Li W, Liu N. Efficacy and safety of PCSK9 inhibitors in patients with diabetes: a systematic review and meta-analysis. Nutr Metab Cardiovasc Dis. 2023;33(9):1647\u201361.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2274_CR26","first-page":"1","volume":"2022","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Suo Y, Yang L, Zhang X, Yu Q, Zeng M, et al. Effect of PCSK9 inhibitor on blood lipid levels in patients with high and very-high CVD risk: a systematic review and meta-analysis. Mancusi C, editor. Cardiol Res Pract. 2022;2022:1\u201313.","journal-title":"Cardiol Res Pract"},{"issue":"6","key":"2274_CR27","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/FJC.0000000000001419","volume":"81","author":"Z Yu","year":"2023","unstructured":"Yu Z, Hu L, Sun C, Wang Z, Zhang X, Wu M, et al. Effect of different types and dosages of proprotein convertase subtilisin\/kexin type 9 inhibitors on lipoprotein(a) levels: a network meta-analysis. J Cardiovasc Pharmacol. 2023;81(6):445\u201353.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"2274_CR28","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1194\/jlr.M012526","volume":"52","author":"S Lamon-Fava","year":"2011","unstructured":"Lamon-Fava S, Marcovina SM, Albers JJ, Kennedy H, DeLuca C, White CC, et al. Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study. J Lipid Res. 2011;52(6):1181\u20137.","journal-title":"J Lipid Res"},{"issue":"1","key":"2274_CR29","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/clinchem\/hvaa247","volume":"67","author":"PR Kamstrup","year":"2021","unstructured":"Kamstrup PR. Lipoprotein(a) and cardiovascular disease. Clin Chem. 2021;67(1):154\u201366.","journal-title":"Clin Chem"},{"issue":"6","key":"2274_CR30","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.001937","volume":"4","author":"C Li","year":"2015","unstructured":"Li C, Lin L, Zhang W, Zhou L, Wang H, Luo X, et al. Efficiency and safety of proprotein convertase subtilisin\/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials. JAHA. 2015;4(6):e001937.","journal-title":"JAHA."},{"key":"2274_CR31","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1192\/bjp.173.3.231","volume":"173","author":"PK McGuire","year":"1998","unstructured":"McGuire PK, Quested DJ, Spence SA, Murray RM, Frith CD, Liddle PF. Pathophysiology of \u2018positive\u2019 thought disorder in schizophrenia. Br J Psychiatry. 1998;173:231\u20135.","journal-title":"Br J Psychiatry"},{"issue":"3","key":"2274_CR32","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/MCA.0000000000001464","volume":"36","author":"E Hu","year":"2025","unstructured":"Hu E, Wan M. Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a meta-analysis. Coron Artery Dis. 2025;36(3):200\u201310.","journal-title":"Coron Artery Dis"},{"issue":"1","key":"2274_CR33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40256-024-00682-0","volume":"25","author":"M Movahedan","year":"2025","unstructured":"Movahedan M, Ellis UM, Barry AR. Efficacy of proprotein convertase subtilisin\/kexin type 9 inhibitors in patients with heterozygous familial hypercholesterolemia: a meta-analysis. Am J Cardiovasc Drugs. 2025;25(1):47\u201355.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"16","key":"2274_CR34","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/heartjnl-2021-320556","volume":"108","author":"J Li","year":"2022","unstructured":"Li J, Du H, Wang Y, Aertgeerts B, Guyatt G, Hao Q, et al. Safety of proprotein convertase subtilisin\/kexin 9 inhibitors: a systematic review and meta-analysis. Heart. 2022;108(16):1296\u2013302.","journal-title":"Heart"},{"issue":"4","key":"2274_CR35","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.010932","volume":"8","author":"MD Shapiro","year":"2019","unstructured":"Shapiro MD, Minnier J, Tavori H, Kassahun H, Flower A, Somaratne R, et al. Relationship between low-density lipoprotein cholesterol and Lipoprotein(a) lowering in response to PCSK9 inhibition with evolocumab. JAHA. 2019;8(4):e010932.","journal-title":"JAHA."},{"issue":"1","key":"2274_CR36","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","volume":"41","author":"AP Patel","year":"2021","unstructured":"Patel AP, Wang M, Pirruccello JP, Ellinor PT, Ng K, Kathiresan S, et al. Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank. ATVB. 2021;41(1):465\u201374.","journal-title":"ATVB"},{"issue":"377","key":"2274_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069066","volume":"4","author":"Q Hao","year":"2022","unstructured":"Hao Q, Aertgeerts B, Guyatt G, Bekkering GE, Vandvik PO, Khan SU, et al. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations. BMJ. 2022;4(377):e069066.","journal-title":"BMJ"},{"key":"2274_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahjo.2022.100127","volume":"13","author":"AFG Cicero","year":"2022","unstructured":"Cicero AFG, Fogacci F, Zambon A, Toth PP, Borghi C. Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies. Am Heart J Plus Cardiol Res Pract. 2022;13:100127.","journal-title":"Am Heart J Plus Cardiol Res Pract"},{"key":"2274_CR39","doi-asserted-by":"crossref","unstructured":"Cheng Z, Gao M, Liu Y, Yan W, Zhang Z, Jiao N, et al. Safety and efficacy of inclisiran in treating hypercholesterolemia: a systemic review and meta-analysis. Nut Metab Cardiovasc Dis. 2024;103779.","DOI":"10.1016\/j.numecd.2024.10.017"},{"issue":"2","key":"2274_CR40","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2174\/0929867330666230228120601","volume":"31","author":"G Ghasempour","year":"2024","unstructured":"Ghasempour G, Zamani-Garmsiri F, Shaikhnia F, Soleimani AA, Hosseini Fard SR, Leila J, et al. Efficacy and safety of alirocumab and evolocumab as proproteinconvertase subtilisin\/kexin type 9 (PCSK9) inhibitors in familial hypercholesterolemia: a systematic review and meta-analysis. CMC. 2024;31(2):223\u201341.","journal-title":"CMC."},{"issue":"1","key":"2274_CR41","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s12872-024-04057-w","volume":"24","author":"K Hosseini","year":"2024","unstructured":"Hosseini K, Soleimani H, Maleki S, Nasrollahizadeh A, Tayebi S, Nelson J, et al. Early administration of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2024;24(1):395.","journal-title":"BMC Cardiovasc Disord"},{"issue":"4","key":"2274_CR42","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1093\/ehjcvp\/pvad019","volume":"9","author":"E Imbalzano","year":"2023","unstructured":"Imbalzano E, Ilardi F, Orlando L, Pintaudi B, Savarese G, Rosano G. The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. 2023;9(4):318\u201327.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2274_CR43","unstructured":"Justino GB. Early Initiation of PCSK9 inhibitor therapy versus placebo in patients with acute coronary syndrome: a systematic review and meta-analysis."},{"issue":"6","key":"2274_CR44","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ihj.2023.09.005","volume":"75","author":"L Nagendra","year":"2023","unstructured":"Nagendra L, Mahajan K, Gupta G, Dutta D. Impact of early initiation of proprotein convertase subtilisin\/kexin type 9 inhibitors in patients with acute coronary syndrome: a systematic review meta-analysis. Indian Heart J. 2023;75(6):416\u201322.","journal-title":"Indian Heart J"},{"issue":"1","key":"2274_CR45","doi-asserted-by":"publisher","first-page":"40","DOI":"10.7326\/M14-2957","volume":"163","author":"EP Navarese","year":"2015","unstructured":"Navarese EP, Ko\u0142odziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, et al. Effects of proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med. 2015;163(1):40\u201351.","journal-title":"Ann Intern Med"},{"issue":"1","key":"2274_CR46","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41598-017-00316-3","volume":"7","author":"LJ Qian","year":"2017","unstructured":"Qian LJ, Gao Y, Zhang YM, Chu M, Yao J, Xu D. Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials. Sci Rep. 2017;7(1):238.","journal-title":"Sci Rep"},{"issue":"3","key":"2274_CR47","doi-asserted-by":"publisher","first-page":"94","DOI":"10.31083\/j.rcm2503094","volume":"25","author":"J Zhao","year":"2024","unstructured":"Zhao J, Tong X, Peng J, Lyu C, Lu S. Efficacy and safety of psck9 inhibitors on patients with acute coronary syndrome: a systematic review and meta-analysis of randomised controlled trials. Rev Cardiovasc Med. 2024;25(3):94.","journal-title":"Rev Cardiovasc Med"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02274-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02274-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02274-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T10:03:08Z","timestamp":1769853788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02274-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2274"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02274-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yongze Li and Lei Dou are joint corresponding authors. Yongze Li and Lei Dou conceived and designed the study. Zhifeng Wen supervised the study. Wenmei Qiao and Yunfei Feng performed the statistical analysis. All authors contributed to acquisition, analysis, or interpretation of data. Wenmei Qiao and Yongze Li drafted the manuscript. All authors revised the report and approved the final version before submission. Yongze Li is the guarantor and attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Wenmei Qiao, Yunfei Feng, etc., and Yongze Li declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Date Availability Statement"}},{"value":"This study did not involve new experiments on humans or animals. All analyses were based on previously published meta-analyses of randomized controlled trials.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The original studies included in this umbrella review were conducted in accordance with the Declaration of Helsinki, and informed written consent was obtained from participants by the investigators of the respective trials.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}